---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-027769"
form_type: "8-K"
ticker: "ADPT"
cik: "0001478320"
company_name: "Adaptive Biotechnologies Corp"
filed_at: "2022-08-03T23:59:59+00:00"
generated_at: "2026-06-24T05:05:26.667671+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Adaptive Biotech Q2 revenue $43.7M (+13% YoY); MRD up 38%, net loss widens

## Summary
- Revenue $43.7M (+13% YoY); MRD revenue $21.3M (+38%) on 53% test volume growth; Immune Medicine $22.4M (-3%).
- Net loss $52.1M vs $49.3M in Q2 2021; operating expenses $96.2M (+9% YoY).
- Updated FY2022 opex guidance to $410-415M (from $425-435M); revenue reaffirmed at $185-195M.
- Expanded Medicare coverage of clonoSEQ for MRD assessment in DLBCL; signed pan-portfolio agreement with major partner.

## SEC filing metadata
- accession: 0001564590-22-027769
- form_type: 8-K
- ticker: ADPT
- cik: 0001478320
- company_name: Adaptive Biotechnologies Corp
- filed_at: 2022-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1478320/000156459022027769/0001564590-22-027769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1478320/000156459022027769/adpt-8k_20220803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-027769
- JSON: https://secwatch.observer/filing/0001564590-22-027769.json
- Plain text: https://secwatch.observer/filing/0001564590-22-027769.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.